Equities

Kalbe Farma Tbk PT

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Kalbe Farma Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)1,080.00
  • Today's Change-20.00 / -1.82%
  • Shares traded50.57m
  • 1 Year change-16.28%
  • Beta0.4868
Data delayed at least 10 minutes, as of Feb 13 2026 09:13 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products, including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritional, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over-the-counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

  • Revenue in IDR (TTM)34.38tn
  • Net income in IDR3.49tn
  • Incorporated1967
  • Employees12.78k
  • Location
    Kalbe Farma Tbk PTGedung KALBE Let.Jend Suprato Kav. 4JAKARTA PUSAT 10510IndonesiaIDN
  • Phone+62 2 142873888
  • Fax+62 214256326
  • Websitehttps://www.kalbe.co.id
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Supernus Pharmaceuticals Inc11.47tn-321.74bn49.06tn674.00--2.7743.974.28-0.3408-0.340812.0918.380.49340.9594.301,011,185.00-1.384.25-1.795.5889.9187.90-2.8010.411.56--0.00--8.9411.005,512.84-8.16-23.33--
Haw Par Corporation Ltd3.37tn3.34tn49.82tn595.0014.920.915314.5614.771.131.131.1418.440.06315.154.88--6.244.786.444.9055.7553.7898.9690.336.04--0.008372.615.500.06855.404.613.115.92
Catalyst Pharmaceuticals Inc9.73tn3.66tn50.33tn181.0014.203.2611.715.171.711.714.557.470.63413.457.023,194,453.0023.8624.6227.3828.8285.6885.7737.6331.736.40--0.000.0023.4936.89129.5038.7595.70--
Kalbe Farma Tbk PT34.38tn3.49tn50.56tn12.78k14.102.1311.591.4776.6276.62754.10507.011.173.086.472,664,288,000.0012.0512.1715.2415.1539.5040.0610.3110.972.36--0.020652.797.167.5917.135.27-8.8112.47
Twist Bioscience Corp6.59tn-1.29tn50.68tn979.00--6.60--7.69-1.27-1.276.467.440.62826.718.76399,956.10-12.29-24.09-13.97-26.8051.6243.29-19.56-67.763.37--0.00--20.3233.1162.79--23.20--
Joincare Pharmaceutical Group Ind. Co.37.02tn3.33tn50.85tn14.35k15.391.40--1.370.74130.74138.248.130.42112.405.511,059,126.008.298.6017.4518.6661.2862.4219.7017.662.38--0.177627.59-6.175.45-3.909.176.844.56
Hisamitsu Pharmaceutical Co Inc17.55tn2.20tn51.28tn2.80k22.351.6116.902.92276.99276.992,208.133,837.320.47042.643.4256,901,390.006.044.347.254.9959.0557.8312.8410.323.28--0.008650.2910.092.0455.763.0829.890.7127
Shanghai Henlius Biotech Inc14.14tn2.01tn52.42tn3.54k40.959.9117.243.711.721.7212.087.100.53861.735.861,868,170.007.66-3.2113.85-5.7675.7772.5014.22-7.870.504610.470.5185--6.11128.9850.26--10.83--
Emcure Pharmaceuticals Ltd16.45tn1.62tn52.45tn6.73k32.43--21.703.1945.9145.91467.02--------13,148,240.00--8.47--15.8659.9359.3010.118.99--30.68--0.0018.599.3636.7652.1321.35--
Hypera SA22.48tn2.66tn52.97tn9.00k18.191.2214.672.361.281.2810.8519.160.27331.493.04--3.227.373.988.9256.7062.4711.7723.170.8382--0.432749.00-5.9717.70-18.532.4716.391.77
The United Laboratories Intl. Hldgs Ltd.34.39tn7.47tn52.98tn17.40k6.531.295.901.541.911.918.799.700.53972.895.97939,504.0011.719.3717.4614.5447.2444.3321.7015.061.60--0.247226.010.138710.39-1.5432.8937.2545.96
PegBio Co Ltd-215.33tn-215.33tn53.10tn58.00--84.18----------0.749------------------------3.07--0.2439-------1.49------
Prestige Consumer Healthcare Inc18.57tn3.14tn53.19tn600.0017.661.7314.592.863.783.7822.3838.660.32343.076.171,839,343.005.474.135.674.3056.1256.3116.9013.131.938.280.36570.001.103.392.528.57-13.84--
Data as of Feb 13 2026. Currency figures normalised to Kalbe Farma Tbk PT's reporting currency: Indonesian Rupiah IDR

Institutional shareholders

6.30%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Feb 2026719.58m1.54%
Norges Bank Investment Managementas of 30 Jun 2025586.26m1.25%
Swedbank Robur Fonder ABas of 30 Jan 2026455.00m0.97%
BlackRock Fund Advisorsas of 06 Feb 2026317.40m0.68%
MFS International Singapore Pte Ltd.as of 31 Dec 2025260.02m0.56%
PT Schroder Investment Management Indonesiaas of 31 Dec 2024201.33m0.43%
Dimensional Fund Advisors LPas of 05 Feb 2026115.89m0.25%
First Sentier Investors (UK) IM Ltd.as of 31 Jan 2026106.90m0.23%
Geode Capital Management LLCas of 06 Feb 202698.99m0.21%
BlackRock Advisors (UK) Ltd.as of 06 Feb 202686.21m0.18%
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.